Pharvaris N.V.(PHVS)Earnings, Financials & Key Ratios
PHVS•NASDAQ
Price updated Jun 19, 2026
AboutPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.Show more
- Revenue$0
- EBITDA-$169M-16.4%
- Net Income-$176M-30.9%
- EPS (Diluted)-2.97-19.8%
- ROE-65.19%-58.3%
PHVS Key Insights
Pharvaris N.V. (PHVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 42.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PHVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PHVS Price & Volume
Pharvaris N.V. (PHVS) stock price & volume — 10-year historical chart
Loading chart...
PHVS Growth Metrics
Pharvaris N.V. (PHVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-0.71%
Return on Capital
10 Years-55.19%
5 Years-45.75%
3 Years-47.95%
Last Year-62.87%
PHVS Recent Earnings
Pharvaris N.V. (PHVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.70+14.8%
$0.82
Rev
—
—
Q2 2026
Apr 2, 2026Metric
Actual
Est
EPS
$0.85-18.3%
$0.71
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.70+10.3%
$0.78
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.94-8.0%
$0.87
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.70vs $0.82+14.8% | — |
| Q2 2026 | Apr 2, 2026 | $0.85vs $0.71-18.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.70vs $0.78+10.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.94vs $0.87-8.0% | — |
Based on last 12 quarters of dataView full earnings history →
PHVS Peer Comparison
Pharvaris N.V. (PHVS) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KALV | 1.44B | 27.00 | -8.36 | -119.44% | -10.57% | |||
 BCAB | 4.61M | 3.66 | -0.07 | -81.82% | -25.31% | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 CGEM | 923.71M | 15.03 | -4.04 | -51.45% | 0.01 | |||
 IQV | 28.47B | 167.77 | 21.40 | 5.87% | 8.33% | 22.11% | 2.44 |
Compare PHVS vs Peers
Pharvaris N.V. (PHVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHVS Income Statement
Pharvaris N.V. (PHVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 614 | 8.44K | 0 | 0 | 0 | 0 | 0 | 106.45K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | -614▲ 0% | -8.44K▼ 1274.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -106.45K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | -1273.05% | 100% | - | - | - | - | - |
Operating Expenses | 4.31M | 8.96M | 28.5M | 54.14M | 86.71M | 96.91M | 145.69M | 169.82M | 172.53M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 668.12K | 2.6M | 6.26M | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M | 48.31M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 3.65M | 6.36M | 22.24M | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M | 124.22M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.31M▲ 0% | -8.97M▼ 107.8% | -28.51M▼ 218.0% | -54.14M▼ 89.9% | -86.71M▼ 60.2% | -96.91M▼ 11.8% | -145.69M▼ 50.3% | -169.82M▼ 16.6% | -172.64M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -107.85% | -217.96% | -89.91% | -60.17% | -11.76% | -50.33% | -16.57% | - |
EBITDA | 0 | -8.96M | -28.5M | -54.06M | -86.56M | -96.66M | -145.59M | -169.4M | -172.22M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -217.89% | -89.7% | -60.12% | -11.66% | -50.63% | -16.35% | -121.12% |
D&A (Non-Cash Add-back) | 4.31M | 614 | 8.44K | 77.37K | 152.94K | 257.55K | 95K | 418.35K | 419.5K |
EBIT | -4.31M | -8.98M | -29.72M | -54.14M | -86.71M | -96.91M | -145.69M | -169.82M | -170.29M |
Net Interest Income | 0 | 4 | -92.38K | -277.91K | -16.09K | 0 | 5.47M | 0 | 4.77M |
Interest Income | 0 | 4 | 92 | 268 | 16 | 0 | 5.47M | 0 | 4.85M |
Interest Expense | 0 | 0 | 92.47K | 278.18K | 16.11K | 0 | 0 | 0 | 87.82K |
Other Income/Expense | -380 | -18.89K | -1.21M | 11.48M | 11.06M | -2.91M | 13.29M | -3.89M | 5.4M |
Pretax Income | -4.31M▲ 0% | -8.98M▼ 108.3% | -29.72M▼ 230.8% | -42.66M▼ 43.6% | -75.65M▼ 77.3% | -99.83M▼ 32.0% | -132.4M▼ 32.6% | -173.71M▼ 31.2% | -167.24M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 380 | 0 | -94.9K | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M | 1.96M |
Effective Tax Rate % | -0.01% | 0% | 0.32% | -0.16% | -0.9% | -1.05% | -1.38% | -1.14% | -1.17% |
Net Income | -4.31M▲ 0% | -8.98M▼ 108.2% | -29.62M▼ 229.7% | -42.73M▼ 44.2% | -76.33M▼ 78.6% | -100.88M▼ 32.2% | -134.22M▼ 33.1% | -175.7M▼ 30.9% | -169.2M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -108.25% | -229.72% | -44.25% | -78.64% | -32.15% | -33.06% | -30.9% | -9.26% |
Net Income (Continuing) | -4.31M | -8.98M | -29.62M | -42.73M | -76.33M | -100.88M | -134.22M | -175.7M | -169.2M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.14▲ 0% | -0.25▼ 78.6% | -0.85▼ 240.0% | -1.41▼ 65.9% | -2.27▼ 61.0% | -2.63▼ 15.9% | -2.48▲ 5.7% | -2.97▼ 19.8% | -2.59▲ 0% |
EPS Growth % | - | -78.57% | -240% | -65.88% | -60.99% | -15.86% | 5.7% | -19.76% | -0.71% |
EPS (Basic) | -0.14 | -0.25 | -0.85 | -1.41 | -2.27 | -2.63 | -2.48 | -2.97 | - |
Diluted Shares Outstanding | 31.84M | 31.84M | 30.52M | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M | 65.31M |
Basic Shares Outstanding | 31.84M | 31.84M | 30.52M | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M | 65.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PHVS Balance Sheet
Pharvaris N.V. (PHVS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.43M | 20.58M | 100.95M | 211.57M | 166.85M | 397.85M | 289.42M | 299.17M | 257.95M |
Cash & Short-Term Investments | 5.39M | 20.33M | 98.63M | 209.35M | 161.84M | 391.23M | 280.73M | 291.68M | 247.22M |
Cash Only | 5.39M | 20.33M | 98.63M | 209.35M | 161.84M | 391.23M | 280.73M | 291.68M | 247.22M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 210.84K | 569.58K | 700.08K | 382.47K | 1.04M | 2.94M | 4.55M | 4.98M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 4.04M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 1.21M | 5.7K | 582.59K | 620.82K | 0 | 0 | 0 |
Total Non-Current Assets | 0 | 12.93K | 147.84K | 523.4K | 886.24K | 843.1K | 1.96M | 2.29M | 2.11M |
Property, Plant & Equipment | 0 | 12.93K | 48.5K | 351.35K | 626.44K | 455.57K | 1.48M | 1.4M | 1.36M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5.43M▲ 0% | 20.6M▲ 279.0% | 101.1M▲ 390.8% | 212.09M▲ 109.8% | 167.73M▼ 20.9% | 398.69M▲ 137.7% | 291.37M▼ 26.9% | 301.45M▲ 3.5% | 260.06M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 279.03% | 390.83% | 109.78% | -20.91% | 137.7% | -26.92% | 3.46% | -23.86% |
Total Current Liabilities | 481.34K | 1.92M | 5.31M | 6.99M | 18.22M | 14.6M | 22.97M | 29.6M | 22.95M |
Accounts Payable | 246.36K | 517.77K | 656.45K | 2.13M | 5.98M | 2.91M | 4.56M | 5.11M | 2.71M |
Days Payables Outstanding | - | 307.56K | 28.4K | - | - | - | - | - | 13.06K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 206.53K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 875.24K | 1.46M | 461.3K | 429.92K | 7.83M | 11.43M | 12.1M |
Current Ratio | 11.29x | 10.70x | 19.00x | 30.28x | 9.16x | 27.25x | 12.60x | 10.11x | 11.24x |
Quick Ratio | 11.29x | 10.70x | 19.00x | 30.28x | 8.93x | 27.25x | 12.60x | 10.11x | 11.24x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 246.36K | 0 | 0 | 150.75K | 249.42K | 43.56K | 639.04K | 576.59K | 533.13K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 150.75K | 249.42K | 43.56K | 639.04K | 576.59K | 2.02M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 481.34K | 1.92M | 5.31M | 7.14M | 18.47M | 14.65M | 23.61M | 30.18M | 23.48M |
Total Debt | 0 | 0 | 0 | 250.18K | 436.82K | 238.91K | 861.47K | 776.8K | 739.66K |
Net Debt | -5.39M | -20.33M | -98.63M | -209.1M | -161.4M | -390.99M | -279.87M | -290.9M | -246.48M |
Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.43x |
Interest Coverage | - | - | -321.38x | -194.62x | -5384.33x | - | - | - | -1939.02x |
Total Equity | 4.95M▲ 0% | 18.67M▲ 277.0% | 95.79M▲ 412.9% | 204.95M▲ 114.0% | 149.26M▼ 27.2% | 384.05M▲ 157.3% | 267.76M▼ 30.3% | 271.27M▲ 1.3% | 236.58M▲ 0% |
Equity Growth % | - | 277.01% | 412.95% | 113.97% | -27.17% | 157.3% | -30.28% | 1.31% | -33.1% |
Book Value per Share | 0.16 | 0.59 | 3.14 | 6.74 | 4.44 | 10.00 | 4.96 | 4.59 | 3.62 |
Total Shareholders' Equity | 4.95M | 18.67M | 95.79M | 204.95M | 149.26M | 384.05M | 267.76M | 271.27M | 236.58M |
Common Stock | 100.93K | 130.96K | 235.69K | 3.98M | 4.06M | 6.27M | 6.53M | 7.83M | 7.86M |
Retained Earnings | -10.45M | -18.47M | -44.46M | -87.57M | -164.19M | -265.92M | -402.26M | -579.6M | -620.18M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 275.99K | 392.14K | 1.98M | 9.8M | 20.21M | 27.88M | 39.85M | 50.5M | 52.78M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHVS Cash Flow Statement
Pharvaris N.V. (PHVS) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.92M | -6.68M | -21.5M | -44.6M | -67.16M | -93.05M | -120.13M | -137.07M | -148.17M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -70.39% | -221.99% | -107.44% | -50.59% | -38.54% | -29.1% | -14.1% | -37.93% |
Net Income | -4.31M | -8.03M | -26.07M | -42.66M | -75.65M | -99.83M | -132.4M | -173.71M | -169.2M |
Depreciation & Amortization | 0 | 549 | 7.4K | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K | 419.5K |
Stock-Based Compensation | 100.75K | 116.15K | 1.59M | 8.2M | 11.35M | 10.66M | 16.21M | 19.05M | 14.92M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.97K | -3.69K | 1.4M | -11.79M | -11.39M | 1.72M | -10.1M | 9.54M | 4.88M |
Working Capital Changes | 291.55K | 1.24M | 1.57M | 1.58M | 8.38M | -5.86M | 5.89M | 7.62M | -872.67K |
Change in Receivables | -49.52K | -208.73K | -358.74K | -130.5K | 317.61K | -41.05K | -34.32K | -331.34K | -496.92K |
Change in Inventory | 0 | 3.58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 188.45K | 273.69K | 0 | 0 | 0 | 0 | 0 | 0 | -4.81M |
Cash from Investing | 0 | -13.48K | -42.98K | -130.03K | -124.3K | -89.98K | -538.09K | -164.62K | -56.57K |
Capital Expenditures | 0 | -13.48K | -42.98K | -130.03K | -124.3K | -89.98K | -538.09K | -164.62K | -56.57K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 4.51M | 21.63M | 101.2M | 143.67M | 8.65M | 325.39M | 2.68M | 160.61M | 160.62M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | -119.53K | -220.51K | -159.66K | -219.01K | -114.48K |
Equity Issued (Net) | 4.51M | 22.47M | 102.51M | 156.83M | 9.61M | 342.91M | 2.24M | 171.74M | 171.71M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -836.18K | -1.31M | -13.15M | -839.97K | -17.3M | 592K | -10.91M | -10.97M |
Net Change in Cash | 590.2K▲ 0% | 14.94M▲ 2431.5% | 78.3M▲ 424.1% | 110.72M▲ 41.4% | -47.52M▼ 142.9% | 229.39M▲ 582.8% | -110.5M▼ 148.2% | 10.95M▲ 109.9% | 4.78M▲ 0% |
Free Cash Flow | -3.92M▲ 0% | -6.69M▼ 70.7% | -21.54M▼ 222.0% | -44.73M▼ 107.6% | -67.29M▼ 50.4% | -93.14M▼ 38.4% | -120.67M▼ 29.6% | -137.24M▼ 13.7% | -148.23M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -70.73% | -221.99% | -107.63% | -50.43% | -38.42% | -29.56% | -13.73% | -9.77% |
FCF per Share | -0.12 | -0.21 | -0.71 | -1.47 | -2.00 | -2.43 | -2.23 | -2.32 | -2.27 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.74x | 0.73x | 1.04x | 0.88x | 0.92x | 0.90x | 0.78x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHVS Key Ratios
Pharvaris N.V. (PHVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -76.05% | -51.76% | -28.42% | -43.1% | -37.83% | -41.18% | -65.19% | -67.38% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | 854.74% |
Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
Interest Coverage | - | -321.38x | -194.62x | -5384.33x | - | - | - | -1939.02x |
FCF Conversion | 0.74x | 0.73x | 1.04x | 0.88x | 0.92x | 0.90x | 0.78x | 0.88x |
Related:PHVS Dividend History·PHVS Revenue History·PHVS Price History·PHVS P/E History·PHVS Financial Ratios·PHVS Institutional Holders
PHVS Frequently Asked Questions
Pharvaris N.V. (PHVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pharvaris N.V. (PHVS) grew revenue by 0.0% over the past year. Growth has been modest.
Pharvaris N.V. (PHVS) reported a net loss of $169.2M for fiscal year 2025.
Dividend & Returns
Pharvaris N.V. (PHVS) has a return on equity (ROE) of -65.2%. Negative ROE indicates the company is unprofitable.
Pharvaris N.V. (PHVS) had negative free cash flow of $148.2M in fiscal year 2025, likely due to heavy capital investments.